Gerasimos Filippatos is an expert in Cardiology at University General Hospital Attikon (Greece). As of October 2026, ScienceLeadR ranks Gerasimos Filippatos in the top 1% of experts worldwide for Heart Failure, Iron Deficiencies and Iron Metabolism Disorders. Gerasimos Filippatos has authored 1,255 publications, the most recent in 2026, and is an investigator in 56 clinical trials, 7 of them ongoing. SLR score: 4,914 (community average: 125). How the SLR is computed.

LeadR Profile

Gerasimos Filippatos University General Hospital Attikon Greece
4 914 ScienceLeadR Reputation 4914
Network Map

Cardiology

Subspecialties: Nephrology - Endocrinology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Gerasimos Filippatos, MD, Dr HonC, FESC, FHFA, FHFSA (hon)

Dr Filippatos is Professor of Cardiology at the National and Kapodistrian University of Athens and Chair of the Department of Cardiology and Medicine; He was Dean of the School of Medicine, University of Cyprus. He studied Medicine at the University of Patras, GR, and earned his doctorate Cum Laude from the University of Athens. He completed his clinical training in Chicago, USA; and Cambridge, UK. He is past President of the Heart Failure Association of the European Society of Cardiology (ESC). He has served in the ESC Practice Guidelines Committee and the ACC/AHA Heart Failure Guidelines Writing Committee and as International Governor of the American College of Chest Physicians (ACCP).

Dr Filippatos served as Senior Consulting Editor for JACC-HF and Eur H Heart Fail and has been Associate Editor of the European Heart Journal and International Journal of Cardiology; member of the Editorial Board and Guest Editor of many other Cardiology and Critical Care Journals. He has published over 900 articles in peer-reviewed journals (https://pubmed.ncbi.nlm.nih.gov/?term=filippatos+g&sort=date) and authored more than 30 book chapters including the “Acute Heart Failure” chapter in Braunwald’s 9th edition. Chair and/or Member of the Executive / Steering / Adjudication Committee of many major clinical trials. Honorary Member of many Cardiac Societies and Visiting Professor in European Universities. He is in the Thomson Reuters/Clarivate list of Highly Cited Researchers since 2015.


Organizations

Career arc: 1997 - 2026

Source: PubMed

National and Kapodistrian University of Athens

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1255

Citations

Citations: 225 568 1st author: 73 Last author: 146 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Association of serum complement levels with failure of low-density-lipoprotein-cholesterol target attainment in patients after acute coronary syndrome: A prospective, observational study.
PMID 42907272 — cholesterol, ldl, serum, complement c3c, lipoproteins, c-reactive protein, acute coronary syndrome, cholesterol, complement system proteins, therapeutics, lipoproteins, ldl
J Clin Lipidol20260
GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF.
PMID 42852467 — heart failure, heart, diuretics, therapeutics, furosemide, prognosis
Eur J Heart Fail20260
Analysis and Interpretation of a Hierarchical Outcome in a Small Pilot Randomized Trial: An Example in the CORTAHF Trial.
PMID 42839766 — pilots, adrenal cortex hormones, therapeutics, steroids
Eur Heart J Cardiovasc Pharmacother20260
Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis.
PMID 42803273 — kidney diseases, creatinine, hospitalization, serum, heart failure, heart, disease progression, kidney, therapeutics
Eur J Heart Fail20260
Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis.
PMID 41762689 — sodium-glucose transporter 2 inhibitors, pyelonephritis, heart failure, heart, infections
Eur J Heart Fail20262

Clinical Studies 56

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 2

By phase:

Phase 3 22
N/A 12
Phase 2 12
Phase 4 7
Phase 2/Phase 3 2
Phase 3/Phase 4 1

By status:

Completed 36
Recruiting 6
Terminated 6
Active not recruiting 4
Unknown 4

By type:

Interventional 51
Observational 5

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 2
multicentricup10 45

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity
2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research
Phase 3Recruiting2026
202301CPC Redefine HF
2023-508581-15-00 — mortality, safety, heart failure, heart, morbidity
Phase 3Recruiting2024
EASi PROTKT A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes high blood pressure and cardiovascular disease
2025-521188-11-00 — diabetes mellitus, hypertension, safety, blood, cardiovascular diseases, blood pressure, diabetes mellitus, type 2
Phase 3Recruiting2025
ATHENA A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation
2023-506988-34-00 — heart failure, heart, signs and symptoms, research
Phase 3Active not recruiting2024
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME CV)
2024-516652-18-00 — cardiovascular diseases, obesity, therapeutics, overweight
Phase 3Recruiting2025

LeadR Networks

Main global connection map